ClinicalTrials.gg
RecruitingNCT07616128Updated Nov 13, 2026

Study of EVO756 in Adults With Migraine

A Phase 2 interventional study of EVO756, Dose 1 and EVO756, Dose 2 in Migraine, sponsored by Evommune, Inc.. Recruiting at 45 sites in 4 countries. Open to participants aged 18 Years to 64 Years. Per ClinicalTrials.gov, last updated 2026-11-13.

Sponsored by Evommune, Inc. · Phase 2, Interventional, and Prevention

From the registry’s dates

  • Started Jul 2026; still recruiting 3 months later.
Updated Nov 13, 2026First sites in Canada, New Zealand and AustraliaStudy contact changed+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
330
Allocation
Randomized
Ages
18 Years to 64 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 696 studies in Migraine Disorders with a site in United States — 93 open to participants now, 115 under way, 27 of them phase 3. Migraine Disorders · United States.

Planned enrollment
147th of 609
330 · median 78
Started
2026
with 35 others
Phase 2
90 of 696
7 open now
Primary completion
2027-10
later than 59 of 114 live
Registered
677th of 696
by date

Among the 696 studies in Migraine Disorders with a site in United States, this one is the 147th largest by planned enrollment of the 609 interventional ones that give a count, is one of 36 that started in 2026, is one of 90 in phase 2, reaches primary completion later than 59 of the 114 other live ones, and was the 677th registered.

Migraine Disorders

1,658 studies on the registry are indexed under Migraine Disorders; 339 are open to participants now.

Browse Migraine Disorders studies →

Open to participants now

93 of the 696 studies in Migraine Disorders with a site in United States are open now. Recruiting first, the newest first:

87 more — sign in →

All 93 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 217 Migraine Disorders studies recruiting now, 66 (30%) set no upper age limit and 136 (63%) stop at 75 or younger; 44 take children under 18; 37 take healthy volunteers.

This study: 18 Years to 64 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 696 studies in Migraine Disorders with a site in United States, or all of them as a file.
02

Study summary

This study will evaluate the efficacy and safety of EVO756 against placebo in adults with migraine.

03

Conditions studied

  • Migraine

Keywords

  • Migraine Disease
  • Migraine Disorder
  • Migraine Disorders
  • Migraine Headache
  • Migraine Headaches
  • Migraine
  • Migraines
  • Migraine in Adults
  • Migraine Prophylaxis
  • Migraine With Aura
  • Migraine With or Without Aura
  • Migraine With and Without Aura
  • Migraine Without Aura
  • Episodic Migraine Headache
  • Chronic Migraine Headache
04

Who can participate

Ages eligible
18 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Adults aged 18 to \<65 years
  • Migraine with or without aura, per ICHD-3 criteria
  • History of failure with prior preventive migraine treatments
  • Not currently using migraine preventive therapy

Key Exclusion Criteria:

  • Difficulty distinguishing migraine from other headache types or presence of other primary headache disorders
  • Use of certain medications
  • Any medical, psychiatric, neurological, cardiovascular, or laboratory abnormalities
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
330 participants (estimated)

Study arms

  • Experimental
    Dose 1

    Orally administered EVO756, Dose 1 (Daily)

    Drug: EVO756, Dose 1

  • Experimental
    Dose 2

    Orally administered EVO756, Dose 2 (Daily)

    Drug: EVO756, Dose 2

  • Placebo comparator
    Placebo

    Placebo control (Daily)

    Drug: Placebo

Interventions

  • Orally administered EVO756, Dose 1 (Daily)

  • Orally administered EVO756, Dose 2 (Daily)

  • DrugPlacebo

    Placebo Control (Daily)

06

What researchers measure

Primary outcomes

  1. Mean change from baseline in the number of monthly migraine days (MMD)

    Time frame: Last month of the 12-week treatment period

Secondary outcomes

  1. Mean change from baseline in the number of MMD

    Time frame: Weeks 4, 8, and across the treatment period (up to 12-weeks)

  2. Mean change from baseline in the number of monthly headache days (MHD)

    Time frame: Weeks 4, 8, 12, and across the treatment period (up to 12-weeks)

  3. Proportion of subjects achieving ≥50% and ≥75% reduction in MMD

    Time frame: Weeks 4, 8, 12, and across the treatment period (up to 12-weeks)

  4. Proportion of subjects achieving ≥50% and ≥75% reduction in MHD

    Time frame: Weeks 4, 8, 12, and across the treatment period (up to 12-weeks)

  5. Mean change from baseline in monthly acute migraine medication use days

    Time frame: Weeks 4, 8, 12, and across the treatment period (up to 12-weeks)

  6. Occurrence of treatment emergent adverse events (TEAE) and serious adverse events (SAE)

    Time frame: through Week 16

07

Study locations

43 of 45 sites recruiting
  • Trialsphere Corp
    Chandler, Arizona 85286, United States
    Recruiting
  • Buena Park Research Center
    Buena Park, California 90620, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Neuro Pain Research Center
    Fresno, California 93710, United States
    Recruiting
  • Salma Health La Jolla
    La Jolla, California 92037, United States
    Recruiting
  • CA Medical Clinic for Headache
    Los Angeles, California 90067, United States
    Recruiting
  • Diablo Clinical Research dba Flourish Research
    Walnut Creek, California 94598, United States
    Recruiting
  • Denver Neurological Clinic
    Denver, Colorado 80124, United States
    Recruiting
  • Hasbani Neurology
    New Haven, Connecticut 06511, United States
    Recruiting
    • EVO756-MIG001 Research Site · Contactjude@neinh.com · 203-562-8071
  • New England Institute for Neurology and Headache
    Stamford, Connecticut 06905, United States
    Recruiting
  • Clinical Neuroscience Solutions, Inc.
    Jacksonville, Florida 32256, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Apple Medical Research Group, Inc
    Miami, Florida 331216, United States
    Recruiting
  • Blessed Healthcase & Research
    Miami, Florida 33173, United States
    Recruiting
  • Florida Research Center, Inc.
    Miami, Florida 33174, United States
    Recruiting
  • Clinical Neuroscience Solutions, Inc.
    Orlando, Florida 32819, United States
    Recruiting
  • Vantage Clinical Trials
    Tampa, Florida 33614, United States
    Recruiting
  • Premiere Research Institute at Palm Beach Neurology
    West Palm Beach, Florida 33407, United States
    Recruiting
  • Clinical Integrative Research Center of Atlanta
    Atlanta, Georgia 30328, United States
    Recruiting
  • Accel Research Site-Decatur-Alcanza
    Decatur, Georgia 30030, United States
    Recruiting
  • Neurology Center of New England P.C.
    Foxborough, Massachusetts 02035, United States
    Recruiting
  • Mass Institute of Clinical Research
    Westborough, Massachusetts 01581, United States
    Recruiting
  • Michigan Headache and Neurological Institute
    Ann Arbor, Michigan 48104, United States
    Recruiting
  • Quest Research Institute-Alcanza
    Farmington Hills, Michigan 48334, United States
    Recruiting
  • Papillion Research Center - Avacare Clinical Research
    Papillion, Nebraska 68046, United States
    Recruiting
  • Bio Behavoural health
    Toms River, New Jersey 08755, United States
    Recruiting
  • Clinosis - Dent Neurologic Instite
    Amherst, New York 14226, United States
    Recruiting
  • Asheville Neurology Specialists, Pa
    Asheville, North Carolina 28806, United States
    Recruiting
  • Eximia Research NC
    Raleigh, North Carolina 27607, United States
    Recruiting
  • NeuroScience Research Center
    Canton, Ohio 44718, United States
    Recruiting
  • Dayton Center for Neurological Disorders
    Centerville, Ohio 45459, United States
    Recruiting
  • Clinical Trials of South Carolina
    Charleston, South Carolina 29406, United States
    Recruiting
  • Campbell Clinical Research
    Franklin, Tennessee 37067, United States
    Recruiting
  • FutureSearch Trials of Neurology
    Austin, Texas 78731, United States
    Recruiting
  • FutureSearch Trials of Dallas
    Dallas, Texas 75251, United States
    Recruiting
  • SFF Medical Research Group LLC
    Houston, Texas 77018, United States
    Recruiting
  • Mercury Clinical Research Inc. - Houston Neurology Associates
    Houston, Texas 77478, United States
    Recruiting
  • MedStar Health: Headache Center at McLean
    McLean, Virginia 22101, United States
    Recruiting
  • Vaught Neurological Services
    Crab Orchard, West Virginia 25827, United States
    Recruiting
  • Paratus Clinical Research Western Sydney
    Blacktown, New South Wales 2148, Australia
    Recruiting
  • Momentum Clinical Research - Sunshine Melbourne
    Saint Albans, Victoria 3021, Australia
    Recruiting
  • Centre de Recherche St-Louis
    Québec, Quebec G1W 4R4, Canada
    Recruiting
  • Momentum Clinical Research - Auckland
    Auckland, 0622, New Zealand
    Recruiting
  • Momentum Clinical Research - Christchurch
    Christchurch, 8013, New Zealand
    Recruiting
  • Momentum Clinical Research - Hutt Valley
    Upper Hutt, 5018, New Zealand
    Recruiting
  • Momentum Clinical Research - Kapiti
    Waikanae, 5036, New Zealand
    Recruiting
  • Momentum Clinical Research - Wellington
    Wellington, 6021, New Zealand
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

3 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2026 (actual). Primary completion is estimated for Oct 2027, 15 months after the start.

Of 43 industry-sponsored phase 2 interventional studies under Migraine Disorders, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 20. This study's planned 15 months is above that.

Counting every sponsor, half of 73 studies reached it within 15 months; a quarter within 11 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
May 19, 2026
First posted
Jun 1, 2026
StartActual
Jul 29, 2026
Primary completionEst.
Oct 2027
CompletionEst.
Nov 2027
Last update
Nov 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
19 sites added — first sites in Canada, New Zealand and Australia. 2 sites changed recruiting status (2 now active, not recruiting)
Show 2 sites
  • Buena Park Research Center · Buena Park, United StatesRecruiting→Active, not recruiting
  • Clinical Neuroscience Solutions, Inc. · Jacksonville, United StatesRecruiting→Active, not recruiting
Show 19 added (11 United States, 5 New Zealand, 2 Australia, 1 Canada)
  • Hasbani Neurology · New Haven, United States
  • Clinical Integrative Research Center of Atlanta · Atlanta, United States
  • Neurology Center of New England P.C. · Foxborough, United States
  • NeuroScience Research Center · Canton, United States
  • Campbell Clinical Research · Franklin, United States
  • Mercury Clinical Research Inc. - Houston Neurology Associates · Houston, United States
  • MedStar Health: Headache Center at McLean · McLean, United States
  • Centre de Recherche St-Louis · Québec, Canada
  • Momentum Clinical Research - Wellington · Wellington, New Zealand
  • Salma Health La Jolla · La Jolla, United States
  • Denver Neurological Clinic · Denver, United States
  • Papillion Research Center - Avacare Clinical Research · Papillion, United States
  • Dayton Center for Neurological Disorders · Centerville, United States
  • Paratus Clinical Research Western Sydney · Blacktown, Australia
  • Momentum Clinical Research - Sunshine Melbourne · Saint Albans, Australia
  • Momentum Clinical Research - Auckland · Auckland, New Zealand
  • Momentum Clinical Research - Christchurch · Christchurch, New Zealand
  • Momentum Clinical Research - Hutt Valley · Upper Hutt, New Zealand
  • Momentum Clinical Research - Kapiti · Waikanae, New Zealand
across 2 updates, Oct 2, 2026 – Nov 4, 2026
Contact
Study contact changed: n•••@evommune.com · •••4553→p•••@evommune.com · •••2358. See the current contact
Nov 13, 2026
Site contacts
Changed at 2 sites. See the sites
Show 2 sites
  • Buena Park Research Center · Buena Park, United StatesContact removed i•••@buenaparkresearch.com · •••1700
  • Clinical Neuroscience Solutions, Inc. · Jacksonville, United StatesContact removed b•••@cnshealthcare.com · •••5757
Nov 4, 2026
Show all 3 updates
  1. Nov 13, 2026
    Contact Study contact changed: n•••@evommune.com · •••4553→p•••@evommune.com · •••2358. See the current contact
  2. Nov 4, 2026
    10 sites added — first site in Australia. 2 sites changed recruiting status (2 now active, not recruiting)
    Show 2 sites
    • Buena Park Research Center · Buena Park, United StatesRecruiting→Active, not recruiting
    • Clinical Neuroscience Solutions, Inc. · Jacksonville, United StatesRecruiting→Active, not recruiting
    Show 10 added (4 United States, 4 New Zealand, 2 Australia)
    • Salma Health La Jolla · La Jolla, United States
    • Denver Neurological Clinic · Denver, United States
    • Papillion Research Center - Avacare Clinical Research · Papillion, United States
    • Dayton Center for Neurological Disorders · Centerville, United States
    • Paratus Clinical Research Western Sydney · Blacktown, Australia
    • Momentum Clinical Research - Sunshine Melbourne · Saint Albans, Australia
    • Momentum Clinical Research - Auckland · Auckland, New Zealand
    • Momentum Clinical Research - Christchurch · Christchurch, New Zealand
    • Momentum Clinical Research - Hutt Valley · Upper Hutt, New Zealand
    • Momentum Clinical Research - Kapiti · Waikanae, New Zealand
    Site contacts Changed at 2 sites. See the sites
    Show 2 sites
    • Buena Park Research Center · Buena Park, United StatesContact removed i•••@buenaparkresearch.com · •••1700
    • Clinical Neuroscience Solutions, Inc. · Jacksonville, United StatesContact removed b•••@cnshealthcare.com · •••5757
    + 1 other change: verification date
  3. Oct 2, 2026
    9 sites added — first sites in Canada and New Zealand
    Show 9 added (7 United States, 1 Canada, 1 New Zealand)
    • Hasbani Neurology · New Haven, United States
    • Clinical Integrative Research Center of Atlanta · Atlanta, United States
    • Neurology Center of New England P.C. · Foxborough, United States
    • NeuroScience Research Center · Canton, United States
    • Campbell Clinical Research · Franklin, United States
    • Mercury Clinical Research Inc. - Houston Neurology Associates · Houston, United States
    • MedStar Health: Headache Center at McLean · McLean, United States
    • Centre de Recherche St-Louis · Québec, Canada
    • Momentum Clinical Research - Wellington · Wellington, New Zealand

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07616128
Lead sponsor
Evommune, Inc.
Responsible party
Sponsor
First posted
Jun 1, 2026
Start date
Jul 29, 2026
Primary completion
Oct 2027 (estimated)
Completion
Nov 2027 (estimated)
Last update
Nov 13, 2026

Study contacts

Polina Bukshpun
Contact
polina.bukshpun@evommune.com
(818) 536-2358

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: EVO756

Start the discussion